E2F1 Induces Tumor Cell Survival via Nuclear Factor-κB–Dependent Induction of EGR1 Transcription in Prostate Cancer Cells

Zheng, Chaogu; Ren, Zijia; Wang, Hetian; Zhang, Weici; Kalvakolanu, Dhananjaya V.; Tian, Zhigang; Xiao, Weihua

doi:10.1158/0008-5472.can-08-4113

Cited by 52 publications

(42 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To understand the molecular mechanism of PCAF-dependent apoptosis resistance, we investigated genes related to tumor cell survival in cisplatin-resistant cells and PCAF-overexpressing cells. E2F1 has an antiapoptotic function (23)(24)(25) and is acetylated and stabilized by PCAF (16). As expected, E2F1 expression was upregulated in cisplatin-resistant cells and FIGURE 5.…”

Section: Discussionsupporting

confidence: 60%

Enhanced Expression of PCAF Endows Apoptosis Resistance in Cisplatin-Resistant Cells

Hirano

Izumi

Kidani

et al. 2010

Molecular Cancer Research

View full text Add to dashboard Cite

Histone acetyltransferase (HAT) regulates transcription. We have previously shown that two HAT genes, Clock and Tip60, are overexpressed, and upregulate glutathione biosynthesis and the expression of DNA repair genes in cisplatin-resistant cells. To better understand the mechanism of HAT-related drug resistance, we investigated the role of another HAT gene, p300/CBP-associated factor (PCAF ), and found that PCAF was also overexpressed in cisplatin-resistant cells and endowed an antiapoptotic phenotype through enhanced E2F1 expression. PCAF-overexpressing cells showed enhanced expression of E2F1 and conferred cell resistance to chemotherapeutic agents. Downregulation of PCAF decreased E2F1 expression and sensitized cells to chemotherapeutic agents. Moreover, knockdown of PCAF induced G 1 arrest and apoptosis. These results suggest that PCAF is one of pleiotropic factors for drug resistance and seems to be critical for cancer cell growth. Mol Cancer Res; 8(6); 864-72. ©2010 AACR.

show abstract

Section: Discussionsupporting

confidence: 60%

Enhanced Expression of PCAF Endows Apoptosis Resistance in Cisplatin-Resistant Cells

Hirano

Izumi

Kidani

et al. 2010

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…EGR1 or early growth response 1 is a zinc finger protein that has been reported to possess both oncogenic and tumor suppressor properties. Zheng et al have shown that NFkBinduced EGR1 transcription allowed survival of prostate tumor cells, whereas other authors have suggested a proapoptotic role by induction of Bax (37,38). ATF3, or activating transcription factor 3, is a leucine zipper protein involved in cellular stress pathways.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Dalle

Reslan

Horts

et al. 2011

Molecular Cancer Therapeutics

114

View full text Add to dashboard Cite

GA101 is a novel glycoengineered Type II CD20 monoclonal antibody. When compared with rituximab, it mediates less complement-dependent cytotoxicity (CDC). As expected for a Type II antibody, GA101 appears not to act through CDC and is more potent than the Type I antibody rituximab in inducing cell death via nonclassical induction of apoptosis cytotoxicity, with more direct cytotoxicity and more antibody-dependent cell-mediated cytotoxicity. We evaluated the antitumor activity of GA101 against the human-transformed follicular lymphoma RL model in vivo in severe combined immunodeficient mice (SCID) mice. GA101 induced stronger inhibition of tumor growth than rituximab. Combination of GA101 with cyclophosphamide in vivo confirmed the superiority of GA101 over rituximab. Neutralizing the complement system with cobra venom factor partially impaired the antitumor activity of rituximab, but had no impact on the efficacy of GA101. In vitro GA101 more potently induced cell death of RL cells than rituximab. The expression of a limited number of genes was found to be induced by both antibodies after exposure in vitro. Among these, early growth response 1 and activation transcription factor 3 were confirmed to be increased at the protein level, suggesting a possible role of these proteins in the apoptotic signalling of anti-CD20 antibodies. These data imply that GA101 is superior to rituximab not only as a single agent, but also in combination with chemotherapy. These data suggest the presence of novel signalization pathways activated after exposure to anti-CD20 antibodies.

show abstract

“…2, Table III and Table SI), tumor suppressor genes or TFs regulating tumor suppressors were identified for all of the entities including expression of FOXO1 [22] in FL cells, PA2G4 [23] in DLBCL cells, SOX11 [24] in MCL cells, and PRDM2 [25] in CLL. Furthermore, SOX4 and EGR1, known depending on tumor type, to act both as tumor suppressors [26][27][28][29] and oncogenes [30,31] showed lower expression in CLL cells. Finally, HCL cells had a high expression of SOX4, and also a low expression of FOXP1 [32].…”

Section: B-cell Lymphoma Entities Express Unique Sets Of Transcriptiomentioning

confidence: 97%

Identification of uniquely expressed transcription factors in highly purified B‐cell lymphoma samples

et al. 2010

View full text Add to dashboard Cite

Transcription factors (TFs) are critical for B-cell differentiation, affecting gene expression both by repression and transcriptional activation. Still, this information is not used for classification of B-cell lymphomas (BCLs). Traditionally, BCLs are diagnosed based on a phenotypic resemblance to normal B-cells; assessed by immunohistochemistry or flow cytometry, by using a handful of phenotypic markers. In the last decade, diagnostic and prognostic evaluation has been facilitated by global gene expression profiling (GEP), providing a new powerful means for the classification, prediction of survival, and response to treatment of lymphomas. However, most GEP studies have typically been performed on whole tissue samples, containing varying degrees of tumor cell content, which results in uncertainties in data analysis. In this study, global GEP analyses were performed on highly purified, flow-cytometry sorted tumor-cells from eight subgroups of BCLs. This enabled identification of TFs that can be uniquely associated to the tumor cells of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia (HCL), and mantle cell lymphoma (MCL). The identified transcription factors influence both the global and specific gene expression of the BCLs and have possible implications for diagnosis and treatment. Am. J. Hematol. 85:418-425, 2010. V

show abstract

E2F1 Induces Tumor Cell Survival via Nuclear Factor-κB–Dependent Induction of EGR1 Transcription in Prostate Cancer Cells

Cited by 52 publications

References 47 publications

Enhanced Expression of PCAF Endows Apoptosis Resistance in Cisplatin-Resistant Cells

Enhanced Expression of PCAF Endows Apoptosis Resistance in Cisplatin-Resistant Cells

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Identification of uniquely expressed transcription factors in highly purified B‐cell lymphoma samples

Contact Info

Product

Resources

About